TriSalus Reports Q2 2024 Financial Results and Business Update
TriSalus Life Sciences, Inc. (TLSI)
Company Research
Source: Business Wire
Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year periodsReported gross margin of 88% in Q2 2024 and 86% for the six months ended June 30, 2024, compared to 83% and 81%, respectively, in the prior year periodsAnnounces plan to launch the “DELIVER” Program in Q3 2024, clinical trials leveraging the TriNav® Infusion System (TriNav) in complex patient types and aiming to significantly expand the addressable marketExpects to report data from phase 1 trials of nelitolimod in uveal melanoma liver metastases and locally advanced pancreatic cancer via its pancreatic infusion technology in Q4 2024Following demonstrated tolerability and efficacy in a limited number of patients in the checkpoint doublet cohort studying nelitolimod in hepatocellular cancer and intrahepatic cholangiocarcinoma (PERIO-2), Company intends to proceed with only investigator-initiated studies in combination with regiona
Show less
Read more
Impact Snapshot
Event Time:
TLSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSI alerts
High impacting TriSalus Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
TLSI
News
- TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $10.00 price target on the stock.MarketBeat
- TriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference CallBusiness Wire
- TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation [Yahoo! Finance]Yahoo! Finance
- TriSalus Life Sciences Announces Completion of Exchange Offer and Consent SolicitationBusiness Wire
TLSI
Sec Filings
- 9/13/24 - Form 4
- 9/12/24 - Form 4
- 9/10/24 - Form 4
- TLSI's page on the SEC website